Last reviewed 2026-04-23 · How we verify

NPC-01

NPC-01 is a small molecule that targets the SGLT2 receptor.

NPC-01 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes, Heart failure.

At a glance

Mechanism of action

NPC-01 works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes. By reducing glucose reabsorption, NPC-01 also has a diuretic effect, which can help reduce blood pressure.

Approved indications

• Type 2 diabetes
• Heart failure

Common side effects

• Increased risk of diabetic ketoacidosis
• Increased risk of genital yeast infections
• Increased risk of hypotension
• Increased risk of acute kidney injury

Key clinical trials

• Pharmacokinetics of NPC-01 After Single Oral Administration in Healthy Female Volunteers (PHASE3)
• Efficacy and Safety, Long-Term Study of NPC-01 to Treat Dysmenorrhea Associated With Endometriosis (PHASE3)
• Pharmacodynamics of NPC-01/IKH-01; Effect of NPC-01/IKH-01 on Sexual Hormone Concentrations in Healthy Female Volunteers (PHASE3)
• Efficacy and Safety Study of NPC-01 to Treat Dysmenorrhea (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• NPC-01 CI brief — competitive landscape report
• NPC-01 updates RSS · CI watch RSS
• Nobelpharma portfolio CI